| Identification | Back Directory | [Name]
GAT229 | [CAS]
889860-85-9 | [Synonyms]
GAT229
GAT229 >=98% (HPLC)
3-[(1S)-2-nitro-1-phenylethyl]-2-phenyl-1H-indole | [Molecular Formula]
C22H18N2O2 | [MDL Number]
MFCD31697715 | [MOL File]
889860-85-9.mol | [Molecular Weight]
342.39 |
| Chemical Properties | Back Directory | [Boiling point ]
585.8±50.0 °C(Predicted) | [density ]
1.237±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 20 mg/ml | [form ]
A solid | [pka]
7.77±0.18(Predicted) | [color ]
white to beige | [Optical Rotation]
[α]/D -80 to -94°, c =1 in methanol |
| Hazard Information | Back Directory | [Description]
GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(–) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. | [Uses]
GAT229 is a CB1 positive allosteric modulator (PAM) that effectively reduces intraocular pressure (IOP) in high IOP mouse models and enhances CB1 receptor-mediated IOP-lowering effects. A 0.2% GAT229 solution or 10 mg/kg of GAT229 alone significantly reduces IOP. GAT229 is promising for research related to glaucoma and elevated intraocular pressure[1]. | [storage]
Store at -20°C | [References]
[1] Cairns EA, et al. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. DOI:10.1089/jop.2017.0037 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|